Literature DB >> 10216940

Eukaryotic initiation factor eIF2.

S R Kimball1.   

Abstract

eIF2 plays a central role in the maintenance of what is generally considered a rate-limiting step in mRNA translation. In this step, eIF2 binds GTP and Met-tRNAi and transfers Met-tRNAi to the 40S ribosomal subunit. At the end of the initiation process, GTP bound to eIF2 is hydrolyzed to GDP and the eIF2.GDP complex is released from the ribosome. The exchange of GDP bound to eIF2 for GTP is a prerequisite to binding Met-tRNAi and is mediated by a second initiation factor, eIF2B. In what is probably the best-characterized mechanism for the regulation of mRNA translation, phosphorylation of eIF2 on its smallest, or alpha-, subunit converts eIF2 from a substrate of eIF2B into a competitive inhibitor. Thus, phosphorylation of eIF2 alpha effectively prevents formation of the eIF2.GTP.Met-tRNAi complex and inhibits global protein synthesis. Phosphorylation of eIF2 alpha occurs under a variety of conditions including viral infection, apoptosis, nutrient deprivation, heme-deprivation, and certain stresses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216940     DOI: 10.1016/s1357-2725(98)00128-9

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  115 in total

Review 1.  The unfolded protein response in protein aggregating diseases.

Authors:  Alexander Gow; Ramaswamy Sharma
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

2.  Structure of the archaeal translation initiation factor aIF2 beta from Methanobacterium thermoautotrophicum: implications for translation initiation.

Authors:  Pablo Gutiérrez; Michael J Osborne; Nadeem Siddiqui; Jean-François Trempe; Cheryl Arrowsmith; Kalle Gehring
Journal:  Protein Sci       Date:  2004-03       Impact factor: 6.725

3.  Defects in translational regulation mediated by the alpha subunit of eukaryotic initiation factor 2 inhibit antiviral activity and facilitate the malignant transformation of human fibroblasts.

Authors:  Darren J Perkins; Glen N Barber
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

4.  Translational resistance of late alphavirus mRNA to eIF2alpha phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR.

Authors:  Iván Ventoso; Miguel Angel Sanz; Susana Molina; Juan José Berlanga; Luis Carrasco; Mariano Esteban
Journal:  Genes Dev       Date:  2006-01-01       Impact factor: 11.361

5.  Rheb Inhibits Protein Synthesis by Activating the PERK-eIF2α Signaling Cascade.

Authors:  Richa Tyagi; Neelam Shahani; Lindsay Gorgen; Max Ferretti; William Pryor; Po Yu Chen; Supriya Swarnkar; Paul F Worley; Katrin Karbstein; Solomon H Snyder; Srinivasa Subramaniam
Journal:  Cell Rep       Date:  2015-02-07       Impact factor: 9.423

6.  Assessing the components of the eIF3 complex and their phosphorylation status.

Authors:  Adam R Farley; David W Powell; Connie M Weaver; Jennifer L Jennings; Andrew J Link
Journal:  J Proteome Res       Date:  2011-03-02       Impact factor: 4.466

7.  Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V2 receptor-independent pathway.

Authors:  Yusuf Ali; Kaoru Dohi; Ryuji Okamoto; Kan Katayama; Masaaki Ito
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739

8.  Translation initiation factor a/eIF2(-gamma) counteracts 5' to 3' mRNA decay in the archaeon Sulfolobus solfataricus.

Authors:  David Hasenöhrl; Tania Lombo; Vladimir Kaberdin; Paola Londei; Udo Bläsi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-01       Impact factor: 11.205

9.  Crosstalk between the Tor and Gcn2 pathways in response to different stresses.

Authors:  Gro Elise Rødland; Tonje Tvegård; Erik Boye; Beáta Grallert
Journal:  Cell Cycle       Date:  2013-11-26       Impact factor: 4.534

10.  Suppression of osteoclastogenesis through phosphorylation of eukaryotic translation initiation factor 2 alpha.

Authors:  Kazunori Hamamura; Nancy Tanjung; Hiroki Yokota
Journal:  J Bone Miner Metab       Date:  2013-03-28       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.